Zimmer Biomet Holdings, Inc. (ZBH) earnings on August 5, 2026
More Zimmer Biomet Holdings, Inc. earnings
Prior outlook: No statistical edge
Zimmer Biomet's stock rose 2.34% after beating profit and sales estimates and raising its outlook. The price hit an intraday high of 6.60% before settling.
ZBH price around the earnings
98.16
Change: +2.4%
2026-08-05, 20:00 UTC
Start of the measured window
End of the measured window
95.85
97.87
99.88
101.90
95.85
August 5, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: No statistical edge
- Thesis published
- Results released
Perfect 100% beat rate with +4.9% surprise but analyst upside limited to 3.7%, trajectory declined from +25.3 to -5.8.
Context analyzed before publication
- Trend
- Initial run-up followed by recent cooling and a drop, suggesting a shift to neutral/slightly after a strong recent drop.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 2.44
- Analysts covering the stock
- 21
- Average price target
- 99.38
- Lowest price target
- 83
- Highest price target
- 130
- Upside to price target
- 3.7%
- Quarterly earnings growth
- 30.8%
- Revenue growth
- 9.3%
- Forward EPS
- 9
- Trailing EPS
- 3.81
- Analyst moves in the last 60 days
- 2
- Strong buy: 3
- Buy: 6
- Hold: 18
- Sell: 0
- Strong sell: 0
- Strong buy
- 3
- Buy
- 6
- Hold
- 18
- Sell
- 0
- Strong sell
- 0
- July 9, 2026 · BMO Capital: Initiates coverage (Outperform → Market Perform)
- July 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (3)
- Live On CNBC, Sarat Sethi Announces Sold Zimmer Biomet (opens in a new tab) — Benzinga
- BMO Capital Initiates Coverage On Zimmer Biomet Holdings with Market Perform Rating, Announces Price Target of $95 (opens in a new tab) — Benzinga
- Evercore ISI Group Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $110 (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 95.85
- Average true range (ATR)
- 3.1%
- Distance to 52-week high
- -10.1%
- 14-day change (14d)
- +7.8%
- 30-day change (33d)
- +9.5%
- 30-day relative strength
- +6.0%
- SPY change (33d)
- +3.5%
- Nearest support
- 95.22
- Distance to nearest support
- 0.7%
- Nearest resistance
- 96.48
- Distance to nearest resistance
- 0.7%
- Volume accumulation ratio (14d / 46d)
- 1.06
- Major: 95.22 (0.7% away, 0.22 ATR, 44 touches)
- Major: 94.57 (1.3% away, 0.44 ATR, 43 touches)
- Major: 93.89 (2.1% away, 0.67 ATR, 54 touches)
- Major: 96.48 (0.7% away, 0.21 ATR, 30 touches)
- Major: 97.67 (1.9% away, 0.62 ATR, 35 touches)
- Major: 98.46 (2.7% away, 0.89 ATR, 32 touches)
Trends
Evidence
- Average earnings surprise
- +4.9%
- April 28, 2026: actual EPS 2.09 vs estimate 1.86 (surprise +12.2%)
- February 10, 2026: actual EPS 2.42 vs estimate 2.4 (surprise +0.9%)
- November 5, 2025: actual EPS 1.9 vs estimate 1.87 (surprise +1.8%)
- August 7, 2025: actual EPS 2.07 vs estimate 1.98 (surprise +4.8%)
Expected move
- Implied move
- +2.5%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 4.1%
- 75th percentile move
- 7.5%
- 90th percentile move
- 10.6%
- Up / down moves
- 6 / 14
- Average up move
- +4.0%
- Average down move
- -6.0%
Monitoring and close
What Zimmer Biomet Holdings, Inc. reported
- Status
- Finished
| Actual EPS | 2.07 |
|---|---|
| EPS estimate | 2.01 |
| EPS surprise | +3.0% |
| Revenue | $2,177 million |
| Revenue estimate | $2,134 million |
| Revenue surprise | +2.0% |
Zimmer Biomet beat Q2 estimates and raised its 2026 outlook, creating an optimistic view. Shares rose over 5% at market open.
Sources (12)
- Zimmer Biomet reports 4.8% YoY revenue uptick in Q2; raises 2026 outlook (opens in a new tab) — Medical Device Network
- ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market (opens in a new tab) — Zacks
- Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) — Zacks
- Zimmer Biomet raises full-year outlook after second-quarter earnings beat (opens in a new tab) — InvestorsHub
- Zimmer Biomet (NYSE:ZBH) Beats Q2 Earnings Estimates, Shares Gain Over 5% (opens in a new tab) — ChartMill
- Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates (opens in a new tab) — Zacks
- Zimmer Biomet’s (NYSE:ZBH) Q2 CY2026: Beats On Revenue (opens in a new tab) — StockStory
- Zimmer Biomet Holdings Raises FY2026 Adj EPS Guidance from $8.40-$8.55 to $8.47-$8.59 vs $8.48 Est; Raises FY2026 Sales Guidance from $8.437B-$8.602B to $8.553B-$8.635B vs $8.544B Est (opens in a new tab) — Benzinga
- Zimmer Biomet beat expectations: adjusted EPS of $2.07 vs $2.01 estimated, and revenue of $2.177 billion vs $2.134 billion. — Benzinga
- Zimmer Biomet Holdings Q2 Adj. EPS $2.07 Beats $2.01 Estimate, Sales $2.177B Beat $2.134B Estimate (opens in a new tab) — Benzinga
- Zimmer Biomet Announces Second Quarter 2026 Financial Results (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +3.4% pre-market, a move in line with the stock's usual reaction (about 4%). The figures don't confirm the prior scenario: there was no prior directional scenario to check against.
How the stock reacted
- Consolidated
- +2.3%
- Max move
- +6.6%
No verdict: the outlook took no direction, so there is nothing to score as a hit or a miss.